Company intelligence / Profile preview
Vigil Neuroscience
Watertown, Massachusetts, United Statesvigilneuro.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 2
01
Overview
Vigil Neuroscience is advancing two TREM2 agonist programs: iluzanebart (monoclonal antibody) in Phase 2 for ALSP with final analysis planned for Q2 2025, and VG-3927 (small molecule) in Phase 1 for Alzheimer's disease with data expected in Q1 2025. Interim Phase 1 data for VG-3927 showed robust decrease of sTREM2 in CSF demonstrating clinical proof-of-target engagement[6].
- Therapeutic areas
- Neurology
- Modalities
- Monoclonal antibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sanofi (strategic investment of $40 million in 2024)[3]
Beyond the preview
Go deeper on Vigil Neuroscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vigil Neuroscience.